ATE267213T1 - Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind - Google Patents

Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Info

Publication number
ATE267213T1
ATE267213T1 AT98948429T AT98948429T ATE267213T1 AT E267213 T1 ATE267213 T1 AT E267213T1 AT 98948429 T AT98948429 T AT 98948429T AT 98948429 T AT98948429 T AT 98948429T AT E267213 T1 ATE267213 T1 AT E267213T1
Authority
AT
Austria
Prior art keywords
cea
agonists
antagonists
peptides
antigen
Prior art date
Application number
AT98948429T
Other languages
English (en)
Inventor
Jeffrey Schlom
Elene Barzaga
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE267213T1 publication Critical patent/ATE267213T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98948429T 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind ATE267213T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10
PCT/US1998/019794 WO1999019478A1 (en) 1997-10-10 1998-09-22 Agonist and antagonist peptides of carcinoembryonic antigen (cea)

Publications (1)

Publication Number Publication Date
ATE267213T1 true ATE267213T1 (de) 2004-06-15

Family

ID=22036775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Country Status (11)

Country Link
EP (1) EP1017810B1 (de)
JP (1) JP4291508B2 (de)
AT (2) ATE364048T1 (de)
AU (1) AU745863B2 (de)
CA (1) CA2308127C (de)
CY (1) CY1107706T1 (de)
DE (2) DE69837896T2 (de)
DK (1) DK1447414T3 (de)
ES (2) ES2217585T3 (de)
PT (1) PT1447414E (de)
WO (1) WO1999019478A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
DE69941703D1 (de) * 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
CA2388337C (en) * 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1305414A2 (de) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Modifiziertes cea und entsprechende verwendungen
WO2003059379A2 (en) * 2002-01-17 2003-07-24 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
EP1567014B1 (de) * 2002-12-04 2011-09-28 Baylor Research Institute Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
KR101455222B1 (ko) * 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
WO2005114444A1 (en) 2004-04-30 2005-12-01 America Online, Inc. Network configuration management
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
HUE032379T2 (en) 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584266B1 (de) * 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
JP4291508B2 (ja) 2009-07-08
PT1447414E (pt) 2007-07-18
DE69824023D1 (de) 2004-06-24
EP1017810B1 (de) 2004-05-19
CY1107706T1 (el) 2013-04-18
WO1999019478A1 (en) 1999-04-22
DE69837896T2 (de) 2008-02-14
JP2002500002A (ja) 2002-01-08
ES2286530T3 (es) 2007-12-01
ATE364048T1 (de) 2007-06-15
AU9500498A (en) 1999-05-03
EP1017810A1 (de) 2000-07-12
CA2308127C (en) 2011-03-22
DE69824023T2 (de) 2005-05-12
CA2308127A1 (en) 1999-04-22
DE69837896D1 (de) 2007-07-19
DK1447414T3 (da) 2007-09-10
AU745863B2 (en) 2002-04-11
ES2217585T3 (es) 2004-11-01

Similar Documents

Publication Publication Date Title
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
ATE272070T1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
NO923953D0 (no) Peptider
MY109957A (en) Improved antibodies to plasmodium falciparum
EP0606317A4 (en) Saponin-antigen conjugates and the use thereof.
DE69316948D1 (de) Lösliche Liganden für CD40
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
EA199800946A1 (ru) Концентрированный препарат антител
GEP20074091B (en) Cripto blocking antibodies and uses thereof
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
TR199801722T2 (xx) Peptit imm�nojenler.
GEP20105118B (en) Anti-vegf antibodies
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
GR3026219T3 (en) Mouse monoclonal antibodies
BG101024A (bg) Моноклонално антитяло срещу сd44v6
EP0739350A4 (de) Fas-antigenbindender ligand
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
EP1447414A3 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
EP1555316A3 (de) Antigenbibliothek Immunisierung
IT8320377A0 (it) Nuovo antigene per la ricerca della ipersensibilita' cutanea brucellica, specialmente nell'uomo. e suo procedimento di preparazione.
DE60237588D1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
ES2199047A1 (es) Metodo de diagnostico inmunologico de la dirofilariosis pulmonar humana

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties